Postoperative Pain After Video-Assisted Thoracoscopic Lobectomy (VATS Lobectomy)
Conditions
Interventions
Low-dose oliceridine group:Postoperative intravenous analgesia with low-dose oliceridine
High-dose oliceridine group:Postoperative intravenous analgesia with high-dose oliceridine
Sponsors
Affiliated Hospital of Jiangnan University
Eligibility
Sex/Gender
All
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=45 years; 2.ASA Physical Status Grades I-III; 3.BMI 18-30 kg/m^2; 4.Patients undergoing first-time elective radical resection of lung cancer via video-assisted thoracic surgery (VATS) under general anesthesia, with an estimated surgical duration of 1-3 hours; 5.Patients planned to receive patient-controlled intravenous analgesia (PCIA) postoperatively, and who can understand the specific criteria for the Numerical Rating Scale (NRS) for pain, Ramsay Sedation Score, and the method for using the analgesic pump; 6.Postoperative hospital stay >= 3 days, and able to cooperate in completing the follow-up assessment within Postop 72h.
Exclusion criteria
Exclusion criteria: 1.Preoperatively unable to communicate due to cognitive impairment or language impairment; 2.Patients classified by cognitive impairment criteria using the preoperative Mini-Mental State Examination (MMSE): those with a score of < 27, and patients diagnosed with preoperative delirium via the Confusion Assessment Method (CAM); 3.Individuals with respiratory depression, high risk of respiratory depression, Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS), or a STOP-Bang score of = 3; 4.Individuals with contraindications or allergies to investigational drugs (such as oliceridine, sufentanil, etc.); 5.Individuals with a history of drug abuse and/or alcohol abuse within the past 3 months; 6.Individuals with suspected or confirmed digestive system obstruction; 7.Individuals with comorbid severe diseases, such as abnormal liver and kidney function, abnormal lung function, or heart failure; 8.Individuals with craniocerebral injury, possible presence of intracranial hypertension, cerebral aneurysm, history of cerebrovascular accident, or those with central nervous system (CNS) diseases (such as epilepsy); 9.The electrocardiogram (ECG) shows QT prolongation; 10.Individuals with psychiatric disorders, or those on long-term administration of psychotropic medications; 11.Individuals estimated to be unable to assess pain intensity postoperatively, or those transferred to the ICU postoperatively; 12.Individuals with incomplete medical record data, or those who did not complete follow-up; 13.Individuals who have participated in clinical studies of other drugs or medical devices within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative delirium (POD);Postoperative Sleep Quality;POD-related laboratory biochemical indicators;Adverse cardiovascular events and eespiratory depression;Rescue analgesics;Quality of Postoperative Recovery;Gastrointestinal reactions;Sedation Score; | — |
Countries
China
Contacts
Public ContactJiru Zhang
Affiliated Hospital of Jiangnan University
Outcome results
None listed